TABLE 7.

Inhibition constants (Ki) and IC50 of inhibitors of C. albicans Sap2

InhibitorSap2 Ki (nM)IC50 (nM)In vivo effects
Pepstatin2.9a27aProtective effect in murine and rat mucosal models (45, 49). Lack of protection in murine disseminated-infection models (58, 64, 188, 258). Possible protection in murine peritonitis (117).
Ritonavir300b2,000aTherapeutic effect in a rat vaginitis model (29).
Saquinavir6,800b300,000aNot tested in vivo.
Indinavir>106b100,000aTherapeutic effect in a rat vaginitis model (29).
A-704500.17a1.4aNo protection in a murine disseminated-infection model (1, 227).
A-79912NDc3.8aNo protection in a murine disseminated-infection model (1, 227).
Peptidomimetics0.6-14.4bNDNot tested in vivo.
  • a Values from references 1 and 226. IC50s of ritonavir, saquinavir, and indinavir are rough estimates based on data presented in reference 15.

  • b Values from reference 168.

  • c ND, not determined.